



Media contacts:

Tissue Genesis, Inc.

Tom Cannon

Phone: 808-539-9331

Email: tcannon@tissuegenesis.com

For Immediate Release

September 7, 2010

Tissue Genesis Receives NASA Honor Award

NASA Award Recognizing Exceptional Contribution to STL-131

Tissue Genesis has been honored with the prestigious NASA Ames Team Honor Award for outstanding contribution to the successful execution of a Space Shuttle payload experiment on STS-131, which launched on April 5, 2010. The awards ceremony was held last week at the NASA Ames Research Center in Moffat Field, California.

NASA Honor Awards are granted annually to individuals and teams that have distinguished themselves through outstanding contributions to the space agency's mission. Each award is approved by the NASA administrator and presented to a select group of individuals and teams.

In collaboration with the Walter Reed Army Institute for Research, The Department of Defense (DoD) Space Test Program, the NASA Ames Research Center, Johnson Space Center, and the Kennedy Space Center, Tissue Genesis led the integration effort of the Space Tissue Loss Project Team to successfully implement cell biology research experiments on the Shuttle Discovery. The research experiment aligned with fundamental NASA space biology objectives and DoD mission goals for wound healing and tissue regeneration in soldiers and combat casualty care.

The Tissue Genesis team, led by Tom Cannon, worked to integrate two cell biology experiments in the Cell Culture Module (CCM), an automated cell biology experiments system. Developed by Mr. Cannon and flown on 17 successful space shuttle missions, the CCM is designed to help scientists study the effects of microgravity on living systems in space. The experiments looked at why cells degenerate at an accelerated rate in space, how cells develop into specialized tissue types, and how cells respond to bacterial infection during spaceflight. Increased understanding of cell biology in microgravity translates

to on earth medical solutions for regenerative medicine and treatment of infectious diseases. This successful experiment payload has resulted in scientific gains highly relevant to NASA and the DoD.

“We are honored that the Tissue Genesis team was recognized for its contributions to NASA’s world class research and to be an active participant in the regenerative medicine revolution,” said Anton Krucky, President and CEO of Tissue Genesis. “Under the leadership of Tom Cannon, the innovation of the CCM hardware and the ability of our team to work across geographic and organizational boundaries continue to bring additional spaceflight opportunities.” Team members included Cristine Kosnik, Anthony Yang, Cheryl Shimoda, Joshua Nelson, and May Lee.

Tissue Genesis is an adult stem cell therapy and regenerative medicine company based in Honolulu, Hawaii.

About Tissue Genesis

An emerging leader in adipose-derived cell therapy and regenerative medicine, Tissue Genesis, Inc. is a high-growth, clinical-stage company based in Honolulu, Hawai‘i. Industry-leading engineers and scientists have developed a proprietary process for Tissue Genesis that may deliver innovative medical solutions for a wide range of existing medical problems, including: cardiac and peripheral vascular disease; orthopedic injuries; cosmetic and soft tissue defects; and many other applications. For more information, visit www.tissuegenesis.com.

Tissue Genesis Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Tissue Genesis, Inc., and members of its management as well as the assumptions on which such statements are based. There can be no assurance that Tissue Genesis will be able to commercially develop its therapeutic cell technology or products, that necessary regulatory approvals will be obtained, that any clinical trials will be successful, or that the proposed treatments will prove to be safe and/or effective. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

###